Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Debt: 2013-2024

Historic Total Debt for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $601.9 million.

  • Amphastar Pharmaceuticals' Total Debt rose 2.15% to $609.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $609.5 million, marking a year-over-year increase of 2.15%. This contributed to the annual value of $601.9 million for FY2024, which is 2.01% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Total Debt stood at $601.9 million for FY2024, which was up 2.01% from $590.0 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Total Debt registered a high of $601.9 million during FY2024, and its lowest value of $46.4 million during FY2020.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Total Debt value was $590.0 million (recorded in 2023), while the average stood at $422.6 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Total Debt fell by 1.46% in 2020, and later soared by 677.51% in 2023.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Total Debt stood at $46.4 million in 2020, then skyrocketed by 65.73% to $77.0 million in 2021, then dropped by 1.42% to $75.9 million in 2022, then soared by 677.51% to $590.0 million in 2023, then increased by 2.01% to $601.9 million in 2024.